This study assesses the effectiveness of both preoperative chemoradiation with cisplatin and fluorouracil or carboplatin and paclitaxel on recurrence-free survival and overall survival in patients with esophageal cancer.
This study uses disease registry data to examine the association between time intervals from the completion of neoadjuvant chemoradiotherapy to surgical procedure and rates of pathologic complete responses in patients with esophageal cancer.
This narrative review summarizes recent advances in the management of localized pancreatic cancer, including the rationale for neoadjuvant treatment sequencing and new diagnostic biomarkers in development.
This case series describes outcomes for patients with borderline resectable pancreatic cancer treated with preoperative chemotherapy, and the details of how collaborating Oncology Study Groups coordinated and conducted the study.
This study reports that patients with node-positive esophageal adenocarcinoma benefit significantly from neoadjuvant chemoradiation, while patients with node-negative tumors do not gain significant overall survival as compared with surgery alone.
This retrospective medical record review examines the role of positron emission tomography–computed tomography characteristics in esophageal adenocarcinoma for patients undergoing neoadjuvant chemoradiotherapy and demonstrates that a δ standardized uptake variable value of less than 45% reliably predicts patients who have residual disease but not complete pathologic response.
This review describes new technologies and treatment options that will continue to advance the treatment of rectal cancer by a multidisciplinary team.
This Viewpoint examines the trends and predictors of the use of radiation for localized unresectable pancreatic cancer.
Brar et al define optimal treatment strategies for gastric adenocarcinoma. See also the invited commentary by Schulick.